Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
Manuela di FuscoKinga MarczellKristen A DegerMary M MoranTimothy L WiemkenAlejandro CaneSolène de BoisvilliersJingyan YangShailja VaghelaJulie RoizPublished in: Journal of medical economics (2022)
The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) contributed to generate substantial public health impact and vaccine-preventable cost savings in the first year of its rollout in the US. The vaccine was estimated to prevent millions of COVID-19 symptomatic cases and thousands of hospitalizations and deaths, and these averted outcomes translated into cost-savings in the billions of US dollars and thousands of QALYs saved. As only direct impacts of vaccination were considered, these estimates may be conservative.